Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 162

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 162
---
 years, the issuance, scope, validity, enforceability and commercial value of any future patent rights are highly uncertain. Our future patent applications may not result in granted patents that protect our drugs or technologies which would render us unable to prevent others from commercializing competitive drugs or technologies. The coverage of patent claims may be significantly reduced during patent prosecution before the patent is granted and the scope can also be reinterpreted after grant, which may not provide us meaningful protection, may not allow us to exclude competitors or may not provide us with any competitive advantage. We may not be able to protect and enforce our trademarks. Currently, we have a broad and diversified portfolio of trademarks, which represents a valuable asset for our company. Certain of our trademarks are registered in Mexico, Paraguay, Panama, Costa Rica, Argentina, Peru, Chile, Colombia, Panama and the Dominican Republic. However, this registry diversity may also pose challenges, particularly in terms of potential litigation, such as oppositions to applications for trademarks similar to ours. In addition, we have not yet registered certain of our trademarks in all of our potential markets. As we apply to register our unregistered 58 trademarks in the U.S. and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. For example, our application to register the “Rewell” trademark in Colombia was rejected in 2022, was denied by the relevant governmental authority because it was deemed confusingly similar to RECELL, a trademark previously registered by AVITA MEDICAL LTD in related, though not identical, products and services. On August 31, 2022, an appeal was filed to contest this decision, but it was also rejected, which prohibits us from using the trademark in that jurisdiction and may continue to do so in the future as we continue the planned expansion of the “Rewell” trademark. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In certain countries outside of the U.S., trademark registration is required to enforce trademark rights. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. Any future patents covering our products and services could be found invalid or unenforceable if challenged. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our future patents or patent applications, including licensed patents, may be challenged